You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歐康維視生物(01477.HK)中期錄得虧損17.42億元,已擁有16種藥物資產
格隆匯 08-26 16:38

格隆匯8月26日丨歐康維視生物(01477.HK)公佈,截至2020年6月30日止6個月,公司錄得收益人民幣200萬元,包括(i)人民幣150萬元乃歸屬於有關歐沁®及酒石酸溴莫尼定滴眼液的推廣服務;及(ii)人民幣0.4百萬元乃歸屬於銷售OT-401,而於截至2019年6月30日止六個月並無產生收益,以及錄得虧損及全面開支總額人民幣17.42億元,而於截至2019年6月30日止六個月則為人民幣2.48億元。

期內,研發開支為人民幣5210萬元,較截至2019年6月30日止六個月的人民幣3080萬元上升69%,乃主要由於擴展研發能力以及就公司主要產品的臨牀試驗及研發活動所產生的開支增加。

截至2020年6月30日,已擁有16種藥物資產,涵蓋所有主要的眼睛前部及後部疾病。我們有四種主要候選藥物正在中國處於開發階段,公司相信,倘獲批准,該等候選藥物將可能屬同類首創或同類最佳,並最早於2022年展示顯著的短期收益潛力。公司的產品組合包括自2015年以來獲FDA批准但未以任何工藝在中國上市的十種眼科藥物中的其中三種。此外,我們的產品組合包括三種處於或臨近商業化階段的藥物。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account